Pharmaceuticals

HENGRUI PHARMA

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Hanson Pharmaceuticals Transfers Exclusive License of Osteoarthritis Drug to Hengrui

BOC International raises Hengrui Medicine target price to 74 HKD

Citi Gives Hengrui Medicine H Shares 'Buy' Rating with Target Price

UBS Adjusts Hengrui Medicine's Profit Forecast and Maintains Buy Rating

HENGRUI PHARMA released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue HKD 9.229 B (forecast HKD 9.384 B), actual EPS HKD 0 (forecast HKD 0.3986)

Hengrui Medicine reports 21.78% increase in first quarter net profit

Hengrui Medicine's Subsidiary's SHR-A1811 Inclusion in Breakthrough Therapy List

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS9531 Injection

Hengrui Medicine's Subsidiary's Drug SHR-A2102 Included in Breakthrough Therapy List

Hengrui Medicine's subsidiary receives clinical trial approval for new heart failure drug HRS-7156

HENGRUI PHARMA to Release FY2026 Q1 Earnings on April 22 After-Market (BJT), Forecast Revenue HKD 9.977 B, EPS HKD 0.3984

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01276

Yesterday's closing, HENGRUI PHARMA's Hong Kong stocks traded significantly actively, with a total transaction amount reaching HKD 464 million, which is considered high in the pharmaceutical sector. The stock price has recently been steadily climbing along the 5-day moving average, with the short-term moving average system showing a bullish arrangement. The MACD daily level has initially established a bullish signal, which usually indicates that the buying power is shifting from a wait-and-see approach to actively entering the market, and the momentum for confirming the short-term trend is beginning to strengthen. The volume is relatively ideal, and there are clear signs of a rebound in capital participation enthusiasm. On the news front, the global pharmaceutical industry has recently seen a continuous increase in attention, with Eli Lilly's oral weight loss drug research progress being widely discussed in the market. The GLP-1 sector continues to attract capital inflows, driving expectations for overall valuation recovery in the innovative drug sector. As a leading domestic innovative drug company, HENGRUI PHARMA has multiple research pipelines in critical clinical stages, and the market has high expectations for its overseas progress and commercialization of innovative drugs. Recently, capital inflows into the Hong Kong pharmaceutical sector have significantly accelerated, and the willingness of southbound funds to allocate to high-quality innovative drug targets has increased. The sector's linkage effect provides additional support for individual stock trends. From a technical perspective, HENGRUI PHARMA's current 5-day and 10-day moving averages are both rising, forming the first short-term support. If today's trading volume can maintain above HKD 400 million and stabilize above the short-term moving averages, the probability of challenging the previous range high points is increasing. However, after a continuous strengthening, intraday fluctuations are unavoidable, and if there is a pullback after a peak during the session, attention should be paid to changes in volume and the performance of HENGRUI PHARMA in the A-share market. The short-term trend reference is slightly bullish, with technical aspects and sector sentiment forming a phase resonance, but caution is needed for accumulated profit-taking after consecutive rebounds

Technical Forecast

Hengrui Pharma

Eli Lilly

Pre-market trend | HENGRUI PHARMA (1276.HK) on May 13th surged with increased volume leading the pharmaceutical sector, is the bullish momentum about to start?

600276

516500

159859

512290

PILL

159849

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Bristol Myers Squibb

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

iShares US Pharma

ALPS Medical Breakthrough

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

ProShares Ultra Health Care ETF

E Fund CSI 300 Health Care ETF

Health Care Select Sector SPDR

Ping An CSI Medicine and Medical Device Innovation ETF

iShares Global Healthcare

Yinhua CSI Innovative Drugs Industry ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Direxion Pharma & Medical Bull 3X

VG Health

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

Bristol-Myers Squibb Company

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

520880

520690

159506

513120

Hengrui Pharmaceutical's shares surged after announcing a USD15.2 billion deal with Bristol Myers Squibb (BMS) to co-develop 13 innovative drugs. Hengrui's stock rose 4.8% in Shanghai and 5.7% in Hong Kong. The agreement grants Hengrui exclusive rights in China, while BMS retains global rights. BMS will pay Hengrui USD950 million upfront, with additional milestone payments, and Hengrui will receive royalties on net sales outside China. The deal awaits regulatory approval and is expected to finalize in Q3 2023, enhancing both companies' drug development capabilities.

Yicai

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

159102

Jiangsu Hengrui Pharmaceutical has signed a $15.2 billion collaboration and licensing agreement with Bristol Myers Squibb (BMS). Hengrui's shares rose 5.3% in Hong Kong and 4.84% in Shenzhen following the announcement. The deal includes 13 preclinical programs, with BMS paying up to $950 million upfront. This partnership highlights China's growing role in innovative drug development, although experts note the need for further advancements in the pharmaceutical value chain. Hengrui will receive tiered royalties on sales outside mainland China, Hong Kong, and Macau.

SCMP

Huaan Hang Seng Biotech ETF

TIGERMED

Tigermed

上海镁信健康科技集团股份有限公司

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

06656

01766

06869

00857

02513

00100

06288

02476

02338

SIGENERGY(06656) rose 6.7%, with a trading turnover 173.6 Million HKD, and a year-to-date rose 74.3%. HENGRUI PHARMA(01276) rose 4.84%, with a trading turnover 1.4 Billion HKD, and a year-to-date fell 2.5%. KNOWLEDGE ATLAS(02513) fell 6.56%, with a trading turnover 779.8 Million HKD, and a year-to-date rose 622.9%. MINIMAX-W(00100) fell 6.31%, with a trading turnover 881.7 Million HKD, and a year-to-date rose 318.5%.

HENGRUI PHARMA(01276.HK)

Pre-market trend | HENGRUI PHARMA (1276.HK) on May 13th surged with increased volume leading the pharmaceutical sector, is the bullish momentum about to start?

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Top 5 HK Stock Gainers/Losers (>100B) (5.12)